Marc Miravitlles1, Vladimir Koblizek2, Cristina Esquinas3, Branislava Milenkovic4, Adam Barczyk5, Ruzena Tkacova6, Attila Somfay7, Kirill Zykov8, Neven Tudoric9, Kosta Kostov10, Zuzana Zbozinkova11, Michal Svoboda11, Jurij Sorli12, Alvils Krams13, Arschang Valipour14. 1. Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. Electronic address: mmiravitlles@vhebron.net. 2. Department of Pneumology, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic. 3. Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. 4. Clinic for Pulmonary Diseases, Faculty of Medicine, Clinical Center of Serbia, Belgrade, Serbia. 5. Department of Pneumology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 6. Department of Respiratory Medicine and Tuberculosis, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia. 7. Department of Pulmonology, University of Szeged, Deszk, Hungary. 8. Pulmonology Scientific Research Institute under FMBA of Russia, Moscow State University of Medicine and Dentistry Named after A.I.Evdokimov, Russia. 9. School of Medicine Zagreb, University Hospital Dubrava, Zagreb, Croatia. 10. Clinic of Pulmonary Diseases, Military Medical Academy, Sofia, Bulgaria. 11. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 12. Pulmonary Department, Topolsica Hospital, Topolsica, Slovenia. 13. Faculty of Medicine, University of Latvia, Riga, Latvia; Riga East University Hospital, Latvia. 14. Department of Respiratory and Critical Care Medicine, Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Spital, Wien, Austria.
Abstract
BACKGROUND: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. METHODS: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. RESULTS: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. CONCLUSIONS: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT >10 is not equivalent to mMRC >2 for assessing symptom burden. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT02119494.
BACKGROUND: The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. METHODS: The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT and modified Medical Research Council (mMRC) scores when used to classify patients according to the GOLD strategy. RESULTS: The study included 3452 patients (69.2% men, mean forced expiratory volume in 1 s (FEV1% predicted) 52.5%). The mean CAT score was 17.5 (SD = 7.8), ranging from 15.1 in Hungary to 21.2 in Bulgaria. Multiple linear regression analysis showed six variables significantly associated with CAT scores: depression, number of previous exacerbations, 6-min walking distance, FEV1(%), mMRC and country and explained 47.2% of the variance of CAT. According to either CAT or mMRC, up to 23.9% patients would be classified in different GOLD groups. CONCLUSIONS: The CAT score may be predicted by factors related to COPD severity, depression and exercise capacity, with significant differences in the distribution of CAT scores in different countries. According to our results CAT >10 is not equivalent to mMRC >2 for assessing symptom burden. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT02119494.
Authors: Hana Müllerová; Mark T Dransfield; Byron Thomashow; Paul W Jones; Stephen Rennard; Niklas Karlsson; Malin Fageras; Norbert Metzdorf; Stefano Petruzzelli; Jean Rommes; Frank C Sciurba; Maggie Tabberer; Debora Merrill; Ruth Tal-Singer Journal: Am J Respir Crit Care Med Date: 2020-05-01 Impact factor: 21.405
Authors: Tereza Hendrychova; Michal Svoboda; Josef Maly; Jiri Vlcek; Eva Zimcikova; Tomas Dvorak; Jaromir Zatloukal; Eva Volakova; Marek Plutinsky; Kristian Brat; Patrice Popelkova; Michal Kopecky; Barbora Novotna; Vladimir Koblizek Journal: Front Pharmacol Date: 2022-08-12 Impact factor: 5.988